Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
Key Highlights
- ➤EU grants Edesa (EDSA) orphan designation for paridiprubart in ARDS
- ➤Designation offers potential 10-year EU market exclusivity after approval
- ➤Phase 2/3 data showed statistically significant survival improvement in ventilated patients
- ➤Paridiprubart program advances toward regulatory discussions and strategic partnerships
Expert Statements
Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech
“The European Commission’s decision is an important regulatory milestone for paridiprubart and recognizes the urgent need for new therapies in ARDS, a condition with high mortality and no approved pharmacological treatments.”
Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech
“Building on the survival benefit observed in our Phase 3 study, we believe this designation strengthens the paridiprubart program as we advance regulatory discussions and strategic partnerships to bring this potential therapy to patients in Europe and other major markets.”
* Designation provides access to EU regulatory incentives, including potential market exclusivity of 10 years following approval TORONTO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the European Commission (EC) has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS).
The designation follows a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products, recognizing both the high mortality rates in ARDS and the need for new treatment options for patients.
Get started
Create a free account to read the full story.
